A 28-year-old man presented with several months of abdominal pain, lower extremity edema, and a 25 pound weight loss. His past medical history was notable for a right lobe hepatoblastoma (HB) that was successfully resected and treated with adjuvant chemotherapy over 25 years ago. Physical examination was notable for mild tenderness in the right upper quadrant with a liver edge palpated 4 cm below the costal margin. He had a well-healed surgical scar across his abdomen, but the remainder of his exam was unremarkable. His bilirubin was 1.6 mg/dL, aspartate transaminase was 29 U/L, alanine transaminase was 60 U/L, and his alkaline phosphatase was 293 U/L. Viral serologies, anti-mitochondrial antibodies, anti-smooth muscle antibodies, and anti-nuclear antibodies were negative. Ceruloplasmin, iron studies, and immunoglobulins were normal. An alpha-fetoprotein was 15,308 ng/mL. A magnetic resonance scan of his abdomen revealed a 7.1 cm x 6.4 cm x 5.7 cm heterogenous mass within segment 4B with additional scattered masses throughout the remainder of the liver (Figure 1) . A computerized tomogram of his chest revealed small nodules consistent with metastatic disease.
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Multiple small core needle biopsies were taken of the liver mass and demonstrated a uniform po-pulation of polygonal cells with clear cytoplasm and hyperchromatic monomorphic nuclei growing in large masses in a macrotrabecular array (Figures 2 and 3). There were no stromal or ductal elements, or evidence of primitive or embryonal differentiation. Mitoses were absent and necrosis was not a feature. The surrounding liver parenchyma was without cirrhosis. Immunohistochemistry was negative for HMB-45, AFB, CD-15, HepPar-1, SMA, Vimentin, and polyclonal CEA. The findings were felt to be most consistent with well-differentiated hepatocellular carcinoma (HCC) with clear cell features, and not a recurrent HB. The dominant mass was treated with Yttrium-90 labeled microspheres. Post-procedure magnetic resonance imaging showed no interval decrease in tumor size, but further palliative radioembolization is planned.
We describe the diagnosis and management of a clear cell HCC arising 25 years after the patient was successfully treated for HB as an infant. HB is the most common childhood primary liver tumor, but it is exceptionally rare with only about 100 cases documented each year. The peak incidence is between six months and three years of age. 1, 2 In patients with limited-extension HB, surgical resection and adjuvant multi-agent chemotherapy with cisplatin-based regimens remains the gold standard of treatment. Chemoembolization, radiofrequency ablation, and liver transplantation have been used for surgically unresectable tumors. Primary clear cell carcinoma of the liver, a histopathological variant of HCC, is also rare and accounts for 7.5-12.5% of liver cancers. 3 Compared to HCC, primary clear cell carcinoma has a better prognosis and does better with surgical resection.
The genetic basis of liver tumors continues to be debated. Recent research suggests that some HCCs may develop from maturation arrest of liver stem cells instead of dedifferentiation of mature hepatocytes. Due to the fact that HB is a stem-like cell carcinoma and similar overlapping groups of upregulated and downregulated genes exist in both HCC and HB, HB may be an early form of some types of HCC. 4 Other data from microsatellite analysis and comparative genomic hybridization has suggested that despite common involvement of a few distinct chromosomes, the patterns of chromosomal alterations and molecular mechanisms are unique among HCC and HB. 5 A better understanding of the molecular, genetic, and clinicopathological basis of these two rare hepatic malignancies will help shed light on the etiology and risk factors involved in liver tumorigenesis. 
